Prognostic Impact of ANX7-GTPase in Metastatic and HER2-Negative Breast Cancer Patients

Clinical Cancer Research

Volumn 10, Issue 7, 2004, Pages 2344-2350

  Srivastava, Meera ^a   Bubendorf, Lukas ^b   Raffeld, Mark ^c   Bucher, Christoph ^b   Torhorst, Jochen ^b   Sauter, Guido ^b   Olsen, Cara ^a   Kallioniemi, Olli P ^d   Eidelman, Ofer ^a   Pollard, Harvey B ^a  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^b UNIVERSITY OF BASEL   (Switzerland)

^c NATIONAL CANCER INSTITUTE   (United States)

^d NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; GUANOSINE TRIPHOSPHATASE; MONOCLONAL ANTIBODY; PROGESTERONE RECEPTOR; PROTEIN P53; SYNEXIN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER SURVIVAL; CHROMOSOME 10Q; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; STATISTICAL ANALYSIS; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; ANNEXIN A7; BLOTTING, WESTERN; BREAST NEOPLASMS; CYTOPLASM; DISEASE PROGRESSION; FEMALE; GTP PHOSPHOHYDROLASES; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM METASTASIS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHENOTYPE; PROGNOSIS; RECEPTOR, ERBB-2; REGRESSION ANALYSIS; RISK; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 11144353711     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-03-0278     Document Type: Article

References (16)

1. 2+-signaling and insulin secretion in the anx7 (+/-) knockout mouse. Proc Natl Acad Sci USA 1999;96:13783-8.
2. Srivastava M, Bubendorf LL, Nolan L, et al. ANX7, a candidate tumor-suppressor gene for prostate cancer. Proc Natl Acad Sci USA 2001;98:4575-80.
3. Srivastava M, Bubendorf LL, Nolan L, et al. ANX7 as a biomarker in prostate and breast cancer progression. Disease Markers 2001;17: 115-20.
4. 2+-activated GTPase activity in vitro and in vivo. Proc Natl Acad Sci USA 1996; 93:10797-802.
5. Caohuy H, Pollard HB. Activation of annexin 7 by protein kinase C in vitro and in vivo. J Biol Chem 2001;276:12813-21.
6. Caohuy H, Pollard HB. Protein kinase C and guanosine triphosphate combine to potentiate calcium-dependent membrane fusion driven by annexin 7. J Biol Chem 2002;277:25217-25.
7. Raynal P, Pollard HB. Annexins: the problem of assessing the biological role for a gene family of multifunctional calcium- and phospholipid-binding proteins. BBA Biomembranes 1994;1197:63-93.
8. 2+ channels in phosphatidylserine bilayer membranes. Proc Natl Acad Sci USA 1988;85:2974-8.
9. Emmert-Buck MR, Gillespie JW, Paweletz CP, et al. An approach to proteomic analysis of human tumors. Mol Carcinog 2000;27:158-65.
10. Paweletz CP, Ornstein DK, Roth MJ, et al. Loss of annexin 1 correlates with early onset of tumorigenesis in esophageal and prostate carcinoma. Cancer Res 2000;60:6293-7.
11. Pencil SD, Toth M. Elevated levels of annexin 1 protein in vitro and in vivo in rat and human mammary adenocarcinoma. Clin Exp Metastasis 1998;2:113-21.
12. Kononen J, Bubendorf L, Kallionemi A, et al. Tissue microarrays for high-throughput molecular profiling of hundreds of tumor specimens. Nat Med 1998;4:844-7.
13. Torhorst J, Bucher C, Kononen J, et al. Tissue microarrays for rapid linking of molecular changes to clinical endpoints. Am J Pathol 2002; 159:2249-56.
14. Bubendorf L, Sauter G, Moch H, et al. Prognostic significance of Bcl-2 in clinically localized prostate cancer. Am J Pathol 1996;148: 1557-65.
15. Bubendorf L, Kolmer M, Kononen J, et al. Molecular mechanisms of hormone therapy failure in human prostate cancer analyzed by a combination of cDNA and tissue microarrays J Natl Cancer Inst (Bethesda) 1999;91:1758-64.
16. Schraml P, Kononen J, Bubendorf L, et al. Tissue microarrays for gene amplification surveys in many different tumor types. Clin Cancer Res 1999;5:1966-75.